Global Herceptin Biosimilars Market – Industry Trends and Forecast to 2030
Global Herceptin Biosimilars Market, By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, and Others), Dosage (150mg/single-dose vial and 420mg/multidose vial), End-Users (Specialty Clinics, Hospitals, Oncology Centers, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2030.
Data Bridge Market Research analyses that the market which was USD 1,810 million in 2022, would rocket up to USD 11,302 million by 2030 and is expected to undergo a CAGR of 23.2% during the forecast period. This indicates the market value. “Breast Cancer” dominates the application segment of the Herceptin Biosimilars market owing to the growing prevalence of breast cancer globally.
Access Full 350 Pages PDF Report @
https://www.databridgemarketresearch.com/reports/global-herceptin-biosimilars-market
**Segments**
- Product Type: The Herceptin biosimilars market can be segmented based on the product type into Trastuzumab, Lapatinib, Pertuzumab, T-DM1, and others. Trastuzumab biosimilars hold a significant share in the market due to their efficacy in treating HER2-positive breast cancer.
- Application: In terms of application, the market can be segmented into Breast Cancer, Gastric Cancer, Esophageal Cancer, and others. Breast cancer application dominates the market as HER2-positive breast cancer is the most common indication for Herceptin biosimilars.
- Distribution Channel: The distribution channel segment includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies hold the largest share in the market due to the preference for administration of biosimilars under medical supervision.
**Market Players**
- Biocon
- Amgen Inc.
- Mylan N.V.
- Celltrion Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Samsung Bioepis
- Merck & Co., Inc.
- ELI Lilly and Company
- Shanghai Henlius Biotech, Inc.
The Herceptin biosimilars market is witnessing significant growth due to the rising incidence of HER2-positive breast cancer and the increasing demand for cost-effective treatment options. The market segmentation based on product type, application, and distribution channel provides insights into the diversified market landscape. Trastuzumab biosimilars dominate the market, especially in the treatment of breast cancer, which remains the leading application segment. The availability of biosimilars through hospital pharmacies further boosts market revenue as patients prefer medical supervision during treatment.
Market players such as Biocon, Amgen Inc., and Mylan N.V. are actively involved in the development and commercialization of Herceptin biosimilars, contributing to market expansion. Companies like Celltrion Inc., PfizerThe Herceptin biosimilars market is a thriving sector within the biopharmaceutical industry, driven by the increasing prevalence of HER2-positive breast cancer and the growing need for cost-effective treatment alternatives. As market players continue to innovate and introduce competitive biosimilar products, the market is experiencing significant growth and expansion. Companies such as Biocon, Amgen Inc., and Mylan N.V. are at the forefront of developing and commercializing Herceptin biosimilars, aiming to capture a substantial share of the market.
One of the key factors fueling the growth of the Herceptin biosimilars market is the segmentation based on product type. Trastuzumab biosimilars hold a prominent position in the market due to their proven efficacy in treating HER2-positive breast cancer, which is a prevalent indication for Herceptin biosimilars. The steady demand for Trastuzumab biosimilars for breast cancer treatment drives substantial revenue in the market, making it a dominant product type segment.
Furthermore, the segmentation based on applications sheds light on the diverse treatment areas where Herceptin biosimilars are utilized. Breast cancer application emerges as the leading segment, reflecting the high incidence of HER2-positive breast cancer cases globally. The efficacy of Herceptin biosimilars in treating breast cancer has propelled the growth of this application segment, making it a key revenue generator for market players.
In terms of distribution channels, hospital pharmacies play a crucial role in the market dynamics. The preference for administering biosimilars under medical supervision has led to the dominance of hospital pharmacies in the distribution channel segment. Patients seeking treatment with Herceptin biosimilars often opt for hospital pharmacies to ensure proper monitoring and care during the course of treatment, driving the revenue for this channel.
The competitive landscape of the Herceptin biosimilars market is characterized by the presence of major players such as Celltrion Inc., Pfizer Inc., and Teva**Segments**
- Product Type: The Herceptin biosimilars market can be segmented into Trastuzumab, Lapatinib, Pertuzumab, T-DM1, and others. Trastuzumab biosimilars are leading the market due to their efficacy in treating HER2-positive breast cancer.
- Application: The market segments based on application include Breast Cancer, Gastric Cancer, Esophageal Cancer, and others. Breast cancer holds the largest share in the market as the most common indication for Herceptin biosimilars.
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies are the distribution channels. Hospital pharmacies dominate the market due to the preference for administering biosimilars under medical supervision.
**Market Players**
- Biocon
- Amgen Inc.
- Mylan N.V.
- Celltrion Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Samsung Bioepis
- Merck & Co., Inc.
- ELI Lilly and Company
- Shanghai Henlius Biotech, Inc.
The Global Herceptin Biosimilars Market has witnessed significant growth due to the rising incidence of HER2-positive breast cancer and the increasing demand for cost-effective treatment options. Market segmentation provides insights into the diversified landscape. Trastuzumab biosimilars dominate the market, especially in breast cancer treatment. Biosimilars availability through hospital pharmacies enhances market revenue as
Highlights of TOC:
Chapter 1: Market overview
Chapter 2: Global Herceptin Biosimilars Market
Chapter 3: Regional analysis of the Global Herceptin Biosimilars Market industry
Chapter 4: Herceptin Biosimilars Market segmentation based on types and applications
Chapter 5: Revenue analysis based on types and applications
Chapter 6: Market share
Chapter 7: Competitive Landscape
Chapter 8: Drivers, Restraints, Challenges, and Opportunities
Chapter 9: Gross Margin and Price Analysis
Core Objective of Herceptin Biosimilars Market:
Every firm in the Herceptin Biosimilars Market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.
- Size of the Herceptin Biosimilars Market and growth rate factors.
- Important changes in the future Herceptin Biosimilars Market.
- Top worldwide competitors of the Market.
- Scope and product outlook of Herceptin Biosimilars Market.
- Developing regions with potential growth in the future.
- Tough Challenges and risk faced in Market.
- Global Herceptin Biosimilars top manufacturers profile and sales statistics.
Regional Analysis for Herceptin Biosimilars Market:
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
- Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
- North America (U.S., Canada, and Mexico)
- South America (Brazil, Chile, Argentina, Rest of South America)
- MEA (Saudi Arabia, UAE, South Africa)
Browse Trending Reports:
Cerebral Vasculitis Treatment Market
Additive Manufacturing With Metal Powders Market
Colistin Sulphate Market
Facioscapulohumeral Muscular Dystrophy Market
Converted Plastic Packaging Market
Local Anesthetics Market
Intelligent Milking Robot Market
Airborne Radars Market
Automotive Emission Test Equipment Market
Wire Cerclage Sternal Closure Systems Market
Collagen Supplements Market
Injectable Drug Delivery Market
Dental Radiology Equipment Market
Clinical Chemistry Analyzer Market
Single Tooth Implants And Dental Bridges Market
Weight Loss And Obesity Management Market
Nerve Repair Biomaterials Market
Medical Device Cleaning Market
Hypercalcemia Treatment Market
x Ray Inspection System Market
Industrial Lighting Market
Industrial Automation Market
Terminal Automation Market
Surgical Sealants Adhesives Market
Medical Gases Market
Ballistic Composites Market
Polyurethane Additives Market
Consumer Iam Market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek